Europe Next Generation Sequencing (NGS) Market: Analysis and Forecast, 2023-2033
This report will be delivered in 1-5 working days.
Introduction to Europe Next Generation Sequencing (NGS) Market
The Europe NGS market was valued at $1.71 billion in 2023 and is expected to reach $5.72 billion by 2033, growing at a CAGR of 12.83% during the forecast period 2023-2033. The Next Generation Sequencing (NGS) market is experiencing growth primarily due to several key factors. These include the declining expenses associated with genome sequencing, the promising applications of NGS in oncology, the increasing prevalence of population-wide genomic research, governmental support for the integration of NGS in healthcare, and the superior attributes of NGS technology when compared to other sequencing methods.
Market Introduction
The Europe Next Generation Sequencing (NGS) market, specifically within the library preparation and sequencing segments, is witnessing substantial growth. Library preparation involves the crucial steps of DNA or RNA fragmentation, amplification, and indexing, making it a fundamental component of NGS workflows. In this context, the market is characterized by the increasing demand for high-throughput and efficient library preparation kits and systems, driven by the expanding applications of NGS in genomics research, clinical diagnostics, and personalized medicine.
The sequencing step, which follows library preparation, is equally significant. Europe's NGS market is marked by a rising adoption of advanced sequencing platforms, including Illumina and Oxford Nanopore technologies, owing to their ability to deliver accurate and rapid sequencing results. This growth is fueled by the escalating need for genomic analysis in various fields, such as healthcare, agriculture, and microbiology, highlighting the pivotal role of library preparation and sequencing products in advancing NGS capabilities in the European region.
Market Segmentation:
Segmentation 1: by Offering
o Sequencing Kits
o Non-Oncology
o Non-Oncology
Segmentation 5: by Country
Type: The Europe NGS market has been segmented based on various categories, such as offerings, throughput, and platform, among others. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Competitive Strategy: The Europe NGS market is consolidated, with a few players accounting for most of the market share. Key players in the Europe NGS market analyzed and profiled in the study involve established players that offer various kinds of NGS platforms, consumables, and services.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Key Companies Profiled:
Introduction to Europe Next Generation Sequencing (NGS) Market
The Europe NGS market was valued at $1.71 billion in 2023 and is expected to reach $5.72 billion by 2033, growing at a CAGR of 12.83% during the forecast period 2023-2033. The Next Generation Sequencing (NGS) market is experiencing growth primarily due to several key factors. These include the declining expenses associated with genome sequencing, the promising applications of NGS in oncology, the increasing prevalence of population-wide genomic research, governmental support for the integration of NGS in healthcare, and the superior attributes of NGS technology when compared to other sequencing methods.
Market Introduction
The Europe Next Generation Sequencing (NGS) market, specifically within the library preparation and sequencing segments, is witnessing substantial growth. Library preparation involves the crucial steps of DNA or RNA fragmentation, amplification, and indexing, making it a fundamental component of NGS workflows. In this context, the market is characterized by the increasing demand for high-throughput and efficient library preparation kits and systems, driven by the expanding applications of NGS in genomics research, clinical diagnostics, and personalized medicine.
The sequencing step, which follows library preparation, is equally significant. Europe's NGS market is marked by a rising adoption of advanced sequencing platforms, including Illumina and Oxford Nanopore technologies, owing to their ability to deliver accurate and rapid sequencing results. This growth is fueled by the escalating need for genomic analysis in various fields, such as healthcare, agriculture, and microbiology, highlighting the pivotal role of library preparation and sequencing products in advancing NGS capabilities in the European region.
Market Segmentation:
Segmentation 1: by Offering
- Consumables
o Sequencing Kits
- Equipment
- Services
- High- and Ultra-High-Throughput
- Medium-Throughput
- Low-Throughput
- Sequencing by Synthesis
- In Torrent Semiconductor Sequencing
- Single Molecule Real-Time Sequencing
- Nanopore Sequencing Technology
- Other Technologies
- Clinical Diagnostics
o Non-Oncology
- Research
o Non-Oncology
Segmentation 5: by Country
- Germany
- U.K.
- France
- Italy
- Spain
- Rest-of-Europe
Type: The Europe NGS market has been segmented based on various categories, such as offerings, throughput, and platform, among others. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
Competitive Strategy: The Europe NGS market is consolidated, with a few players accounting for most of the market share. Key players in the Europe NGS market analyzed and profiled in the study involve established players that offer various kinds of NGS platforms, consumables, and services.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Key Companies Profiled:
- Oxford Nanopore Technologies plc
- Qiagen N.V.
- F. Hoffmann-La Roche Ltd
- Centogene N.V.
- Alithea Genomics
Executive Summary
Scope of the Study
Research Methodology
1 MARKETS
1.1 Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.1.3 Key Findings
1.2 Industry Outlook
1.2.1 NGS: Overview
1.2.2 Historical Trends
1.2.3 Comparative Analysis of Various Technologies
1.2.4 NGS Market: Overview
1.2.5 Emerging NGS Technologies
1.2.5.1 In-Situ Sequencing
1.2.5.2 Microscopy-Based Sequencing
1.2.5.3 Future of Ultra-High Throughput NGS
1.2.6 Current Market Scenario
1.2.6.1 For Researchers
1.2.6.2 For Diagnostics
1.2.7 COVID-19 Impact on the NGS Market
1.2.8 Supply Chain Analysis
1.2.8.1 Key Entities in Supply Chain
1.2.9 Research Publications
1.2.10 Primary Insights
1.2.11 Pricing Analysis
1.3 Business Dynamics
1.3.1 Impact Analysis
1.3.2 Business Drivers
1.3.2.1 Decreasing Cost of Genome Sequencing
1.3.2.2 Potential of NGS in the Field of Oncology Research and as a Companion Diagnostic for Oncology in Clinical Settings
1.3.2.3 Growing Number of Population-Wide Sequencing Studies and Government Initiatives to Integrate NGS in Healthcare
1.3.2.4 Advantages of NGS Technology over Other Technologies
1.3.3 Business Restraints
1.3.3.1 Concerns Surrounding the Privacy of Patient Genomic Data
1.3.3.2 Lack of Complete Reimbursement Coverage for NGS Testing
1.3.4 Business Opportunities
1.3.4.1 Evolving Regulatory Landscape for Clinical NGS
1.3.4.2 Growing Number of Gene Mutations across Various Diseases
2 EUROPE
2.1 Europe NGS Market
2.1.1 Overview
2.1.2 Legal Requirements and Framework in Europe
2.1.3 Market Dynamics
2.1.3.1 Impact Analysis
2.1.4 Key Distributors
2.1.5 Genome Projects
2.1.6 Market Sizing and Forecast, by Value
2.1.6.1 Europe NGS Market (by Offering), by Value
2.1.6.1.1 Europe NGS Market (Equipment), by Value
2.1.6.1.1.1 Europe NGS Market (Equipment, by Company), by Value
2.1.6.1.1.1.1 Europe NGS Market (Equipment, by Illumina, Inc.), by Value
2.1.6.1.1.1.2 Europe NGS Market (Equipment, by Thermo Fisher Scientific Inc.), by Value
2.1.6.1.1.1.3 Europe NGS Market (Equipment, by Pacific Biosciences of California, Inc.), by Value
2.1.6.1.1.1.4 Europe NGS Market (Equipment, by Oxford Nanopore Technologies plc.), by Value
2.1.6.1.2 Europe NGS Market (Equipment), by Volume
2.1.6.1.3 Europe NGS Market (by Throughput), by Value
2.1.6.1.4 Europe NGS Market (by Throughput), by Volume
2.1.6.2 Europe NGS Market (by End User)
2.1.6.2.1 Europe NGS Market (Academic and Research Institutes, by Offering)
2.1.6.2.2 Europe NGS Market (Clinical Laboratories, by Offering)
2.1.6.2.3 Europe NGS Market (Pharmaceutical and Biotechnology Companies, by Offering)
2.1.6.2.4 Europe NGS Market (Other End Users, by Offering)
2.1.6.3 Europe NGS Market (by Technology Type)
2.1.6.4 Europe NGS Market (by Application)
2.1.6.4.1 Europe NGS Market (Application, by Clinical Diagnostics)
2.1.6.4.2 Europe NGS Market (Application, by Research)
2.1.6.5 Europe NGS Market (by Country)
2.1.6.5.1 Germany
2.1.6.5.1.1 Market Dynamics
2.1.6.5.1.2 Market Sizing and Forecast, by Value
2.1.6.5.1.2.1 Germany NGS Market (by Offering), by Value
2.1.6.5.1.2.1.1 Germany NGS Market (Equipment), by Value
2.1.6.5.1.2.1.1.1 Germany NGS Market (Equipment, by Company), by Value
2.1.6.5.1.2.1.2 Germany NGS Market (Equipment), by Volume
2.1.6.5.2 U.K.
2.1.6.5.2.1 Market Dynamics
2.1.6.5.2.2 Market Sizing and Forecast, by Value
2.1.6.5.2.2.1 U.K. NGS Market (by Offering), by Value
2.1.6.5.2.2.1.1 U.K. NGS Market (Equipment), by Value
2.1.6.5.2.2.1.1.1 U.K. NGS Market (Equipment, by Company), by Value
2.1.6.5.2.2.1.2 U.K. NGS Market (Equipment), by Volume
2.1.6.5.3 France
2.1.6.5.3.1 Market Dynamics
2.1.6.5.3.2 Market Sizing and Forecast, by Value
2.1.6.5.3.2.1 France NGS Market (by Offering), by Value
2.1.6.5.3.2.1.1 France NGS Market (Equipment), by Value
2.1.6.5.3.2.1.1.1 France NGS Market (Equipment, by Company), by Value
2.1.6.5.3.2.1.2 France NGS Market (Equipment), by Volume
2.1.6.5.4 Italy
2.1.6.5.4.1 Market Dynamics
2.1.6.5.4.2 Market Sizing and Forecast, by Value
2.1.6.5.4.2.1 Italy NGS Market (by Offering), by Value
2.1.6.5.4.2.1.1 Italy NGS Market (Equipment), by Value
2.1.6.5.4.2.1.1.1 Italy NGS Market (Equipment, by Company), by Value
2.1.6.5.4.2.1.2 Italy NGS Market (Equipment), by Volume
2.1.6.5.5 Spain
2.1.6.5.5.1 Market Dynamics
2.1.6.5.5.2 Market Sizing and Forecast, by Value
2.1.6.5.5.2.1 Spain NGS Market (by Offering), by Value
2.1.6.5.5.2.1.1 Spain NGS Market (Equipment), by Value
2.1.6.5.5.2.1.1.1 Spain NGS Market (Equipment, by Company), by Value
2.1.6.5.5.2.1.2 Spain NGS Market (Equipment), by Volume
2.1.6.5.6 Rest-of-Europe
2.1.6.5.6.1 Market Dynamics
2.1.6.5.6.2 Market Sizing and Forecast, by Value
2.1.6.5.6.2.1 Rest-of-Europe NGS Market (by Offering), by Value
2.1.6.5.6.2.1.1 Rest-of-Europe NGS Market (Equipment), by Value
2.1.6.5.6.2.1.1.1 Rest-of-Europe NGS Market (Equipment, by Company), by Value
2.1.6.5.6.2.1.2 Rest-of-Europe NGS Market (Equipment), by Volume
3 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES
3.1 Competitive Landscape
3.1.1 Overview
3.1.2 Corporate Strategies
3.1.2.1 Mergers and Acquisitions
3.1.2.2 Synergistic Activities
3.1.2.3 Business Expansions and Funding
3.1.3 Business Strategies
3.1.3.1 Product Launches/Upgradations/Approvals
3.2 Market Share Analysis
3.3 Growth-Share Analysis for the NGS Market (by End User)
3.4 Growth-Share Analysis for the NGS Market (by Throughput)
3.5 Company Profiles
3.5.1 Oxford Nanopore Technologies plc.
3.5.1.1 Company Overview
3.5.1.2 Role of Oxford Nanopore Technologies plc. in the NGS Market
3.5.1.3 Recent Developments
3.5.1.4 Financials
3.5.1.5 Target Customers
3.5.1.6 Analyst Perception
3.5.2 Qiagen N.V.
3.5.2.1 Company Overview
3.5.2.2 Role of Qiagen N.V. in the NGS Market
3.5.2.3 Financials
3.5.2.4 Recent Developments
3.5.2.5 Target Customers
3.5.2.6 Analyst’s Perspective
3.5.3 F. Hoffmann-La Roche Ltd
3.5.3.1 Company Overview
3.5.3.2 Role of F. Hoffmann-La Roche Ltd in the NGS Market
3.5.3.3 Financials
3.5.3.4 Recent Developments
3.5.3.5 Target Customers
3.5.3.6 Analyst’s Perspective
3.5.4 Centogene N.V.
3.5.4.1 Company Overview
3.5.4.2 Role of Centogene N.V. in the NGS Market
3.5.4.3 Financials
3.5.4.4 Recent Developments
3.5.4.5 Target Customers
3.5.4.6 Analyst’s Perspective
3.6 Emerging Company Snapshots
3.6.1 Alithea Genomics
3.6.1.1 Company Overview
3.6.1.2 Role of Alithea Genomics in the NGS Market
3.6.1.3 Recent Developments
List of Figures
Figure 1: Europe NGS Market, Impact Analysis
Figure 2: NGS Market (by Region), $Billion, 2022 and 2033
Figure 3: NGS Market Research Methodology
Figure 4: Primary Research Methodology
Figure 5: Bottom-Up Approach (Segment-Wise Analysis)
Figure 6: Top-Down Approach (Segment-Wise Analysis)
Figure 7: NGS Market, NGS Workflow
Figure 8: NGS Market, NGS Applications
Figure 9: Key Milestones in the Development of Modern-Day NGS Technologies
Figure 10: Europe NGS Market, $Billion, 2022-2033
Figure 11: Workflow of In-Situ Sequencing
Figure 12: Workflow of Microscopy-Based Sequencing
Figure 13: Challenges Associated with Multiplex Sequencing and their Solutions
Figure 14: Key Milestones of the Cancer Genome Atlas Program (TCGA)
Figure 15: Key Areas of NGS Application in SARS-CoV-2 Virus Research
Figure 16: NGS Market, Supply Chain Analysis
Figure 17: List of Common Raw Materials and Suppliers in the NGS Market
Figure 18: Number of Research Publications Related to NGS, 2018-2022
Figure 19: Key Primary Insights for the NGS Market
Figure 20: Average Price of NGS Platforms Based on Throughput
Figure 21: NGS Market, Impact Analysis
Figure 22: Cost of Sequencing Human Genome ($), 2001, 2006, and 2021
Figure 23: Estimated Number of New Cancer Cases, Million, 2020, 2030, and 2040
Figure 24: Key Applications of NGS in Clinical Oncology
Figure 25: Some Population-Wide Genome Sequencing Studies in Asia-Pacific
Figure 26: NGS Market, Share of Global Genomic Initiatives in Different Regions (in %)
Figure 27: NGS Informatics Market, Genome Sequencing Initiatives in Europe
Figure 28: Key Features of NGS Technology
Figure 29: Comparison of qPCR vs. NGS Technology
Figure 30: Comparison of Microarray vs. NGS Technology
Figure 31: Comparison of Sanger Sequencing vs. NGS Technology
Figure 32: Key Factors Behind Poor Reimbursement of NGS in Clinical Settings
Figure 33: Evolving Regulatory Landscape for Approval of NGS-Based Tests
Figure 34: Key Requirements for Laboratory-Developed Tests (LDTs) as per the IVDR
Figure 35: Europe NGS Market (by Country)
Figure 36: Europe NGS Market, $Billion, 2022-2033
Figure 37: Europe NGS Market (by Offering), $Billion, 2022-2032
Figure 38: Europe NGS Market (Equipment), $Billion, 2022-2033
Figure 39: Europe NGS Market (Equipment, by Company), $Million, 2022-2033
Figure 40: Europe NGS Market (Equipment, by Illumina, Inc.), $Million, 2022-2033
Figure 41: Europe NGS Market (Equipment, by Thermo Fisher Scientific Inc.), $Million, 2022-2033
Figure 42: Europe NGS Market (Equipment, by Pacific Biosciences of California, Inc.), $Million, 2022-2033
Figure 43: Europe NGS Market (Equipment, by Oxford Nanopore Technologies plc.), $Million, 2022-2033
Figure 44: Europe NGS Market (Equipment), Units, 2022-2033
Figure 45: Europe NGS Market (by Throughput), $Million, 2022-2033
Figure 46: Europe NGS Market (by Throughput), Units, 2022-2033
Figure 47: Europe NGS Market (by End User), $Billion, 2022-2033
Figure 48: Europe NGS Market (Academic and Research Institutes, by Offering), $Million, 2022-2033
Figure 49: Europe NGS Market (Clinical Laboratories, by Offering), $Million, 2022-2033
Figure 50: Europe NGS Market (Pharmaceutical and Biotechnology Companies, by Offering), $Million, 2022-20233
Figure 51: Europe NGS Market (Other End Users, by Offering), $Million, 2022-2033
Figure 52: Europe NGS Market (by Technology Type), $Million, 2022-2033
Figure 53: Europe NGS Market (by Application), $Billion, 2022-2033
Figure 54: Europe NGS Market (Application, by Clinical Diagnostics), $Billion, 2022-2033
Figure 55: Europe NGS Market (Application, by Research), $Billion, 2022-2033
Figure 56: Europe NGS Market (by Country), Share (%), 2022 and 2033
Figure 57: Germany NGS Market, $Billion, 2022-2033
Figure 58: Germany NGS Market (by Offering), $Million, 2022-2033
Figure 59: Germany NGS Market (Equipment), $Million, 2022-2033
Figure 60: Germany NGS Market (Equipment, by Company), $Million, 2022-2033
Figure 61: Germany NGS Market (Equipment), Units, 2022-2033
Figure 62: U.K. NGS Market, $Billion, 2022-2033
Figure 63: U.K. NGS Market (by Offering), $Million, 2022-2033
Figure 64: U.K. NGS Market (Equipment), $Million, 2022-2033
Figure 65: U.K. NGS Market (Equipment, by Company), $Million, 2022-2033
Figure 66: U.K. NGS Market (Equipment), Units, 2022-2033
Figure 67: France NGS Market, $Billion, 2022-2033
Figure 68: France NGS Market (by Offering), $Million, 2022-2033
Figure 69: France NGS Market (Equipment), $Million, 2022-2033
Figure 70: France NGS Market (Equipment, by Company), $Million, 2022-2033
Figure 71: France NGS Market (Equipment), Units, 2022-2033
Figure 72: Italy NGS Market, $Billion, 2022-2033
Figure 73: Italy NGS Market (by Offering), $Million, 2022-2033
Figure 74: Italy NGS Market (Equipment), $Million, 2022-2033
Figure 75: Italy NGS Market (Equipment, by Company), $Million, 2022-2033
Figure 76: Italy NGS Market (Equipment), Units, 2022-2033
Figure 77: Spain NGS Market, $Billion, 2022-2033
Figure 78: Spain NGS Market (by Offering), $Million, 2022-2033
Figure 79: Spain NGS Market (Equipment), $Million, 2022-2033
Figure 80: Spain NGS Market (Equipment, by Company), $Million, 2022-2033
Figure 81: Spain NGS Market (Equipment), Units, 2022-2033
Figure 82: Rest-of-Europe NGS Market, $Billion, 2022-2033
Figure 83: Rest-of-Europe NGS Market (by Offering), $Million, 2022-2033
Figure 84: Rest-of-Europe NGS Market (Equipment), $Million, 2022-2033
Figure 85: Rest-of-Europe NGS Market (Equipment, by Company), $Million, 2022-2033
Figure 86: Rest-of-Europe NGS Market (Equipment), Units, 2022-2033
Figure 87: Share of Key Developments, January 2019-May 2023
Figure 88: Number of Mergers and Acquisitions (by Company), January 2019-May 2023
Figure 89: Share of Synergistic Activities (by Company), January 2019-May 2023
Figure 90: Number of Business Expansions and Funding Activities (by Company), January 2019-May 2023
Figure 91: Share of Product Launches/Upgradations/Approvals (by Company), January 2019-May 2023
Figure 92: Market Share Analysis for NGS Market (by Company), 2022
Figure 93: Growth-Share Analysis for the NGS Market (by End User), 2022
Figure 94: Growth-Share Analysis for the NGS Market (by Throughput), 2022
Figure 95: Share of Companies Profiled
Figure 96: Oxford Nanopore Technologies plc.: Overall Product Portfolio
Figure 97: Oxford Nanopore Technologies plc.: Overall Financials, $Million, 2020-2022
Figure 98: Oxford Nanopore Technologies plc.: Segment Revenue, $Million, 2020-2022
Figure 99: Oxford Nanopore Technologies plc.: Net Revenue (by Region), $Million, 2020-2022
Figure 100: Oxford Nanopore Technologies plc.: R&D Expenditure, $Million, 2020-2022
Figure 101: Qiagen N.V.: Overall Product Portfolio
Figure 102: Qiagen N.V.: Overall Financials, $Million, 2020-2022
Figure 103: Qiagen N.V.: Segment Revenue, $Million, 2020-2022
Figure 104: Qiagen N.V.: Net Revenue (by Region), $Million, 2020-2022
Figure 105: Qiagen N.V.: R&D Expenditure, $Million, 2020-2022
Figure 106: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 107: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
Figure 108: F. Hoffmann-La Roche Ltd: Segment Revenue, $Million, 2020-2022
Figure 109: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022
Figure 110: Centogene N.V.: Overall Product Portfolio
Figure 111: Centogene N.V.: Overall Financials, $Million, 2021-2022
Figure 112: Centogene N.V.: Segment Revenue, $Million, 2021-2022
Figure 113: Centogene N.V.: Net Revenue (by Region), $Million, 2021-2022
Figure 114: Centogene N.V.: R&D Expenditure, $Million, 2021-2022
Figure 115: Alithea Genomics: Overall Product Portfolio
Scope of the Study
Research Methodology
1 MARKETS
1.1 Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.1.3 Key Findings
1.2 Industry Outlook
1.2.1 NGS: Overview
1.2.2 Historical Trends
1.2.3 Comparative Analysis of Various Technologies
1.2.4 NGS Market: Overview
1.2.5 Emerging NGS Technologies
1.2.5.1 In-Situ Sequencing
1.2.5.2 Microscopy-Based Sequencing
1.2.5.3 Future of Ultra-High Throughput NGS
1.2.6 Current Market Scenario
1.2.6.1 For Researchers
1.2.6.2 For Diagnostics
1.2.7 COVID-19 Impact on the NGS Market
1.2.8 Supply Chain Analysis
1.2.8.1 Key Entities in Supply Chain
1.2.9 Research Publications
1.2.10 Primary Insights
1.2.11 Pricing Analysis
1.3 Business Dynamics
1.3.1 Impact Analysis
1.3.2 Business Drivers
1.3.2.1 Decreasing Cost of Genome Sequencing
1.3.2.2 Potential of NGS in the Field of Oncology Research and as a Companion Diagnostic for Oncology in Clinical Settings
1.3.2.3 Growing Number of Population-Wide Sequencing Studies and Government Initiatives to Integrate NGS in Healthcare
1.3.2.4 Advantages of NGS Technology over Other Technologies
1.3.3 Business Restraints
1.3.3.1 Concerns Surrounding the Privacy of Patient Genomic Data
1.3.3.2 Lack of Complete Reimbursement Coverage for NGS Testing
1.3.4 Business Opportunities
1.3.4.1 Evolving Regulatory Landscape for Clinical NGS
1.3.4.2 Growing Number of Gene Mutations across Various Diseases
2 EUROPE
2.1 Europe NGS Market
2.1.1 Overview
2.1.2 Legal Requirements and Framework in Europe
2.1.3 Market Dynamics
2.1.3.1 Impact Analysis
2.1.4 Key Distributors
2.1.5 Genome Projects
2.1.6 Market Sizing and Forecast, by Value
2.1.6.1 Europe NGS Market (by Offering), by Value
2.1.6.1.1 Europe NGS Market (Equipment), by Value
2.1.6.1.1.1 Europe NGS Market (Equipment, by Company), by Value
2.1.6.1.1.1.1 Europe NGS Market (Equipment, by Illumina, Inc.), by Value
2.1.6.1.1.1.2 Europe NGS Market (Equipment, by Thermo Fisher Scientific Inc.), by Value
2.1.6.1.1.1.3 Europe NGS Market (Equipment, by Pacific Biosciences of California, Inc.), by Value
2.1.6.1.1.1.4 Europe NGS Market (Equipment, by Oxford Nanopore Technologies plc.), by Value
2.1.6.1.2 Europe NGS Market (Equipment), by Volume
2.1.6.1.3 Europe NGS Market (by Throughput), by Value
2.1.6.1.4 Europe NGS Market (by Throughput), by Volume
2.1.6.2 Europe NGS Market (by End User)
2.1.6.2.1 Europe NGS Market (Academic and Research Institutes, by Offering)
2.1.6.2.2 Europe NGS Market (Clinical Laboratories, by Offering)
2.1.6.2.3 Europe NGS Market (Pharmaceutical and Biotechnology Companies, by Offering)
2.1.6.2.4 Europe NGS Market (Other End Users, by Offering)
2.1.6.3 Europe NGS Market (by Technology Type)
2.1.6.4 Europe NGS Market (by Application)
2.1.6.4.1 Europe NGS Market (Application, by Clinical Diagnostics)
2.1.6.4.2 Europe NGS Market (Application, by Research)
2.1.6.5 Europe NGS Market (by Country)
2.1.6.5.1 Germany
2.1.6.5.1.1 Market Dynamics
2.1.6.5.1.2 Market Sizing and Forecast, by Value
2.1.6.5.1.2.1 Germany NGS Market (by Offering), by Value
2.1.6.5.1.2.1.1 Germany NGS Market (Equipment), by Value
2.1.6.5.1.2.1.1.1 Germany NGS Market (Equipment, by Company), by Value
2.1.6.5.1.2.1.2 Germany NGS Market (Equipment), by Volume
2.1.6.5.2 U.K.
2.1.6.5.2.1 Market Dynamics
2.1.6.5.2.2 Market Sizing and Forecast, by Value
2.1.6.5.2.2.1 U.K. NGS Market (by Offering), by Value
2.1.6.5.2.2.1.1 U.K. NGS Market (Equipment), by Value
2.1.6.5.2.2.1.1.1 U.K. NGS Market (Equipment, by Company), by Value
2.1.6.5.2.2.1.2 U.K. NGS Market (Equipment), by Volume
2.1.6.5.3 France
2.1.6.5.3.1 Market Dynamics
2.1.6.5.3.2 Market Sizing and Forecast, by Value
2.1.6.5.3.2.1 France NGS Market (by Offering), by Value
2.1.6.5.3.2.1.1 France NGS Market (Equipment), by Value
2.1.6.5.3.2.1.1.1 France NGS Market (Equipment, by Company), by Value
2.1.6.5.3.2.1.2 France NGS Market (Equipment), by Volume
2.1.6.5.4 Italy
2.1.6.5.4.1 Market Dynamics
2.1.6.5.4.2 Market Sizing and Forecast, by Value
2.1.6.5.4.2.1 Italy NGS Market (by Offering), by Value
2.1.6.5.4.2.1.1 Italy NGS Market (Equipment), by Value
2.1.6.5.4.2.1.1.1 Italy NGS Market (Equipment, by Company), by Value
2.1.6.5.4.2.1.2 Italy NGS Market (Equipment), by Volume
2.1.6.5.5 Spain
2.1.6.5.5.1 Market Dynamics
2.1.6.5.5.2 Market Sizing and Forecast, by Value
2.1.6.5.5.2.1 Spain NGS Market (by Offering), by Value
2.1.6.5.5.2.1.1 Spain NGS Market (Equipment), by Value
2.1.6.5.5.2.1.1.1 Spain NGS Market (Equipment, by Company), by Value
2.1.6.5.5.2.1.2 Spain NGS Market (Equipment), by Volume
2.1.6.5.6 Rest-of-Europe
2.1.6.5.6.1 Market Dynamics
2.1.6.5.6.2 Market Sizing and Forecast, by Value
2.1.6.5.6.2.1 Rest-of-Europe NGS Market (by Offering), by Value
2.1.6.5.6.2.1.1 Rest-of-Europe NGS Market (Equipment), by Value
2.1.6.5.6.2.1.1.1 Rest-of-Europe NGS Market (Equipment, by Company), by Value
2.1.6.5.6.2.1.2 Rest-of-Europe NGS Market (Equipment), by Volume
3 MARKETS - COMPETITIVE BENCHMARKING & COMPANY PROFILES
3.1 Competitive Landscape
3.1.1 Overview
3.1.2 Corporate Strategies
3.1.2.1 Mergers and Acquisitions
3.1.2.2 Synergistic Activities
3.1.2.3 Business Expansions and Funding
3.1.3 Business Strategies
3.1.3.1 Product Launches/Upgradations/Approvals
3.2 Market Share Analysis
3.3 Growth-Share Analysis for the NGS Market (by End User)
3.4 Growth-Share Analysis for the NGS Market (by Throughput)
3.5 Company Profiles
3.5.1 Oxford Nanopore Technologies plc.
3.5.1.1 Company Overview
3.5.1.2 Role of Oxford Nanopore Technologies plc. in the NGS Market
3.5.1.3 Recent Developments
3.5.1.4 Financials
3.5.1.5 Target Customers
3.5.1.6 Analyst Perception
3.5.2 Qiagen N.V.
3.5.2.1 Company Overview
3.5.2.2 Role of Qiagen N.V. in the NGS Market
3.5.2.3 Financials
3.5.2.4 Recent Developments
3.5.2.5 Target Customers
3.5.2.6 Analyst’s Perspective
3.5.3 F. Hoffmann-La Roche Ltd
3.5.3.1 Company Overview
3.5.3.2 Role of F. Hoffmann-La Roche Ltd in the NGS Market
3.5.3.3 Financials
3.5.3.4 Recent Developments
3.5.3.5 Target Customers
3.5.3.6 Analyst’s Perspective
3.5.4 Centogene N.V.
3.5.4.1 Company Overview
3.5.4.2 Role of Centogene N.V. in the NGS Market
3.5.4.3 Financials
3.5.4.4 Recent Developments
3.5.4.5 Target Customers
3.5.4.6 Analyst’s Perspective
3.6 Emerging Company Snapshots
3.6.1 Alithea Genomics
3.6.1.1 Company Overview
3.6.1.2 Role of Alithea Genomics in the NGS Market
3.6.1.3 Recent Developments
List of Figures
Figure 1: Europe NGS Market, Impact Analysis
Figure 2: NGS Market (by Region), $Billion, 2022 and 2033
Figure 3: NGS Market Research Methodology
Figure 4: Primary Research Methodology
Figure 5: Bottom-Up Approach (Segment-Wise Analysis)
Figure 6: Top-Down Approach (Segment-Wise Analysis)
Figure 7: NGS Market, NGS Workflow
Figure 8: NGS Market, NGS Applications
Figure 9: Key Milestones in the Development of Modern-Day NGS Technologies
Figure 10: Europe NGS Market, $Billion, 2022-2033
Figure 11: Workflow of In-Situ Sequencing
Figure 12: Workflow of Microscopy-Based Sequencing
Figure 13: Challenges Associated with Multiplex Sequencing and their Solutions
Figure 14: Key Milestones of the Cancer Genome Atlas Program (TCGA)
Figure 15: Key Areas of NGS Application in SARS-CoV-2 Virus Research
Figure 16: NGS Market, Supply Chain Analysis
Figure 17: List of Common Raw Materials and Suppliers in the NGS Market
Figure 18: Number of Research Publications Related to NGS, 2018-2022
Figure 19: Key Primary Insights for the NGS Market
Figure 20: Average Price of NGS Platforms Based on Throughput
Figure 21: NGS Market, Impact Analysis
Figure 22: Cost of Sequencing Human Genome ($), 2001, 2006, and 2021
Figure 23: Estimated Number of New Cancer Cases, Million, 2020, 2030, and 2040
Figure 24: Key Applications of NGS in Clinical Oncology
Figure 25: Some Population-Wide Genome Sequencing Studies in Asia-Pacific
Figure 26: NGS Market, Share of Global Genomic Initiatives in Different Regions (in %)
Figure 27: NGS Informatics Market, Genome Sequencing Initiatives in Europe
Figure 28: Key Features of NGS Technology
Figure 29: Comparison of qPCR vs. NGS Technology
Figure 30: Comparison of Microarray vs. NGS Technology
Figure 31: Comparison of Sanger Sequencing vs. NGS Technology
Figure 32: Key Factors Behind Poor Reimbursement of NGS in Clinical Settings
Figure 33: Evolving Regulatory Landscape for Approval of NGS-Based Tests
Figure 34: Key Requirements for Laboratory-Developed Tests (LDTs) as per the IVDR
Figure 35: Europe NGS Market (by Country)
Figure 36: Europe NGS Market, $Billion, 2022-2033
Figure 37: Europe NGS Market (by Offering), $Billion, 2022-2032
Figure 38: Europe NGS Market (Equipment), $Billion, 2022-2033
Figure 39: Europe NGS Market (Equipment, by Company), $Million, 2022-2033
Figure 40: Europe NGS Market (Equipment, by Illumina, Inc.), $Million, 2022-2033
Figure 41: Europe NGS Market (Equipment, by Thermo Fisher Scientific Inc.), $Million, 2022-2033
Figure 42: Europe NGS Market (Equipment, by Pacific Biosciences of California, Inc.), $Million, 2022-2033
Figure 43: Europe NGS Market (Equipment, by Oxford Nanopore Technologies plc.), $Million, 2022-2033
Figure 44: Europe NGS Market (Equipment), Units, 2022-2033
Figure 45: Europe NGS Market (by Throughput), $Million, 2022-2033
Figure 46: Europe NGS Market (by Throughput), Units, 2022-2033
Figure 47: Europe NGS Market (by End User), $Billion, 2022-2033
Figure 48: Europe NGS Market (Academic and Research Institutes, by Offering), $Million, 2022-2033
Figure 49: Europe NGS Market (Clinical Laboratories, by Offering), $Million, 2022-2033
Figure 50: Europe NGS Market (Pharmaceutical and Biotechnology Companies, by Offering), $Million, 2022-20233
Figure 51: Europe NGS Market (Other End Users, by Offering), $Million, 2022-2033
Figure 52: Europe NGS Market (by Technology Type), $Million, 2022-2033
Figure 53: Europe NGS Market (by Application), $Billion, 2022-2033
Figure 54: Europe NGS Market (Application, by Clinical Diagnostics), $Billion, 2022-2033
Figure 55: Europe NGS Market (Application, by Research), $Billion, 2022-2033
Figure 56: Europe NGS Market (by Country), Share (%), 2022 and 2033
Figure 57: Germany NGS Market, $Billion, 2022-2033
Figure 58: Germany NGS Market (by Offering), $Million, 2022-2033
Figure 59: Germany NGS Market (Equipment), $Million, 2022-2033
Figure 60: Germany NGS Market (Equipment, by Company), $Million, 2022-2033
Figure 61: Germany NGS Market (Equipment), Units, 2022-2033
Figure 62: U.K. NGS Market, $Billion, 2022-2033
Figure 63: U.K. NGS Market (by Offering), $Million, 2022-2033
Figure 64: U.K. NGS Market (Equipment), $Million, 2022-2033
Figure 65: U.K. NGS Market (Equipment, by Company), $Million, 2022-2033
Figure 66: U.K. NGS Market (Equipment), Units, 2022-2033
Figure 67: France NGS Market, $Billion, 2022-2033
Figure 68: France NGS Market (by Offering), $Million, 2022-2033
Figure 69: France NGS Market (Equipment), $Million, 2022-2033
Figure 70: France NGS Market (Equipment, by Company), $Million, 2022-2033
Figure 71: France NGS Market (Equipment), Units, 2022-2033
Figure 72: Italy NGS Market, $Billion, 2022-2033
Figure 73: Italy NGS Market (by Offering), $Million, 2022-2033
Figure 74: Italy NGS Market (Equipment), $Million, 2022-2033
Figure 75: Italy NGS Market (Equipment, by Company), $Million, 2022-2033
Figure 76: Italy NGS Market (Equipment), Units, 2022-2033
Figure 77: Spain NGS Market, $Billion, 2022-2033
Figure 78: Spain NGS Market (by Offering), $Million, 2022-2033
Figure 79: Spain NGS Market (Equipment), $Million, 2022-2033
Figure 80: Spain NGS Market (Equipment, by Company), $Million, 2022-2033
Figure 81: Spain NGS Market (Equipment), Units, 2022-2033
Figure 82: Rest-of-Europe NGS Market, $Billion, 2022-2033
Figure 83: Rest-of-Europe NGS Market (by Offering), $Million, 2022-2033
Figure 84: Rest-of-Europe NGS Market (Equipment), $Million, 2022-2033
Figure 85: Rest-of-Europe NGS Market (Equipment, by Company), $Million, 2022-2033
Figure 86: Rest-of-Europe NGS Market (Equipment), Units, 2022-2033
Figure 87: Share of Key Developments, January 2019-May 2023
Figure 88: Number of Mergers and Acquisitions (by Company), January 2019-May 2023
Figure 89: Share of Synergistic Activities (by Company), January 2019-May 2023
Figure 90: Number of Business Expansions and Funding Activities (by Company), January 2019-May 2023
Figure 91: Share of Product Launches/Upgradations/Approvals (by Company), January 2019-May 2023
Figure 92: Market Share Analysis for NGS Market (by Company), 2022
Figure 93: Growth-Share Analysis for the NGS Market (by End User), 2022
Figure 94: Growth-Share Analysis for the NGS Market (by Throughput), 2022
Figure 95: Share of Companies Profiled
Figure 96: Oxford Nanopore Technologies plc.: Overall Product Portfolio
Figure 97: Oxford Nanopore Technologies plc.: Overall Financials, $Million, 2020-2022
Figure 98: Oxford Nanopore Technologies plc.: Segment Revenue, $Million, 2020-2022
Figure 99: Oxford Nanopore Technologies plc.: Net Revenue (by Region), $Million, 2020-2022
Figure 100: Oxford Nanopore Technologies plc.: R&D Expenditure, $Million, 2020-2022
Figure 101: Qiagen N.V.: Overall Product Portfolio
Figure 102: Qiagen N.V.: Overall Financials, $Million, 2020-2022
Figure 103: Qiagen N.V.: Segment Revenue, $Million, 2020-2022
Figure 104: Qiagen N.V.: Net Revenue (by Region), $Million, 2020-2022
Figure 105: Qiagen N.V.: R&D Expenditure, $Million, 2020-2022
Figure 106: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 107: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
Figure 108: F. Hoffmann-La Roche Ltd: Segment Revenue, $Million, 2020-2022
Figure 109: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022
Figure 110: Centogene N.V.: Overall Product Portfolio
Figure 111: Centogene N.V.: Overall Financials, $Million, 2021-2022
Figure 112: Centogene N.V.: Segment Revenue, $Million, 2021-2022
Figure 113: Centogene N.V.: Net Revenue (by Region), $Million, 2021-2022
Figure 114: Centogene N.V.: R&D Expenditure, $Million, 2021-2022
Figure 115: Alithea Genomics: Overall Product Portfolio
LIST OF TABLES
Table 1: Key Questions Answered in the Report
Table 2: Key Features of Short-Read vs. Long-Read Sequencing
Table 3: Comparison of Key NGS Technologies
Table 4: Some Approved NGS Panels for IVD Use
Table 5: Listed Prices of Key NGS Platforms
Table 6: Clinical NGS-Based Assays for Oncology Offerings by Companies
Table 7: Genome Sequencing Projects in Latin America and the Middle East
Table 8: Status of NGS Reimbursement in Europe
Table 9: Few of the Multi-Gene NGS Panels Available in the Market
Table 10: Legal Requirements and Framework in Europe
Table 11: Europe NGS Market, Impact Analysis
Table 12: Some of the Key Distributors in Europe (by Company)
Table 13: Genome Projects (by Country)
Table 1: Key Questions Answered in the Report
Table 2: Key Features of Short-Read vs. Long-Read Sequencing
Table 3: Comparison of Key NGS Technologies
Table 4: Some Approved NGS Panels for IVD Use
Table 5: Listed Prices of Key NGS Platforms
Table 6: Clinical NGS-Based Assays for Oncology Offerings by Companies
Table 7: Genome Sequencing Projects in Latin America and the Middle East
Table 8: Status of NGS Reimbursement in Europe
Table 9: Few of the Multi-Gene NGS Panels Available in the Market
Table 10: Legal Requirements and Framework in Europe
Table 11: Europe NGS Market, Impact Analysis
Table 12: Some of the Key Distributors in Europe (by Company)
Table 13: Genome Projects (by Country)
